- Active not recruitingPHASE3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
This study is looking into a new combination of medicines for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination with a standard one to see if the new option works better.
For: Relapsed or Refractory Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This study compares a new treatment, AZD0120, with standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new medicine works better and is safe for patients.
For: Relapsed Refractory Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE1, PHASE2
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
This study is testing a new drug called CC-220, sometimes on its own and sometimes with other standard cancer medicines, for people with multiple myeloma. It aims to find the right dose, see how safe it is, and if it helps treat the disease.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE3
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new treatment, teclistamab, with existing therapies for multiple myeloma that has come back or not responded to previous treatments. It aims to see how well teclistamab works and if it's safe for people with this condition.
For: Relapsed or Refractory Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
This study is testing a new medicine called elranatamab for people with a type of blood cancer called multiple myeloma. It's for those whose cancer has returned after other treatments. We want to see if elranatamab works better than standard medicines.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Daratumumab
This study offers ongoing access to specific treatments for people with multiple myeloma or smouldering multiple myeloma who have already benefited from them in previous studies. It helps ensure continued care and collects long-term safety information.
For: Multiple MyelomaUnited States · Belgium · Brazil - Active not recruitingPHASE3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or isn't responding to treatment. It compares a new medicine, etentamig, with existing treatments to see how well they control the cancer.
For: Multiple MyelomaUnited States · Australia · Austria - Not yet recruitingPHASE3
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination (Etentamig plus Pomalidomide) with standard treatments to see if it's safe and helps improve the disease.
For: Relapsed or Refractory Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
This study is testing a new medicine, sonrotoclax, for people in the UK with multiple myeloma that has come back or isn't responding to treatment. Researchers want to see how safe and effective it is, both on its own and with other common myeloma drugs.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE1
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is looking at a new medicine called talquetamab, combined with other treatments, for people with multiple myeloma. The main goal is to find safe doses and understand how well these combinations work together.
For: Multiple MyelomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
This study compares a new treatment called BMS-986393 with standard medicines for adults with multiple myeloma that has come back or not responded to previous treatment, including lenalidomide. We want to see if the new medicine works better and is safe.
For: Relapsed or Refractory Multiple Myeloma (RRMM)United States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
For: Multiple MyelomaUnited States · Australia · Israel - Active not recruitingPHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
This study compares a new treatment called anitocabtagene autoleucel with standard care for people with multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new treatment works better.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE2
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
This study is looking at a new combination of four medicines (Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone) for people with newly diagnosed, high-risk multiple myeloma. It aims to see how safe and effective this treatment is.
For: Multiple MyelomaGermany - Active not recruitingPHASE3
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
This study looks at a new drug combination, E-KRd, for people just diagnosed with multiple myeloma. It adds a drug called Elotuzumab to a standard treatment (KRd) to see if it works better at controlling the cancer and keeping it away for longer.
For: Newly Diagnosed Multiple MyelomaAustria · Germany - Active not recruitingPHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This study looks at a new treatment, bb2121, for multiple myeloma that has come back or isn't responding to common medicines. It compares bb2121 with standard treatments to see which works best and is safest for patients aged 18 and over.
For: Multiple MyelomaUnited States · Belgium · Canada - RecruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
This study looks at a new way to give belantamab mafodotin, along with other common medicines, for multiple myeloma that has come back or isn't responding well. We want to see if giving it less often can still work well and cause fewer eye side effects.
For: Multiple MyelomaUnited States · France · Germany - RecruitingPHASE3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study looks at a new drug, linvoseltamab, for multiple myeloma that has come back or isn't responding to treatment. It compares linvoseltamab alone or with another drug, carfilzomib, against standard treatments to see if it's safer and works better.
For: Relapsed and/or Refractory Multiple Myeloma (RRMM)United States · Australia · South Korea - Active not recruiting
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
This study looks at how a medicine called isatuximab works for people in the UK with a type of blood cancer called multiple myeloma that has come back or not responded to previous treatments. It checks how well it works and if it's safe in real-world settings.
For: Plasma Cell MyelomaUnited States · Argentina · Austria